Correction to: Human skin-derived ABCB5+ stem cell injection improves liver disease parameters in Mdr2KO mice
- 153 Downloads
Correction to: Archives of Toxicology (2019) 93:2645–2660 https://doi.org/10.1007/s00204-019-02533-3
We wish to submit a corrigendum to the above-mentioned article. Thank you very much for consideration and publication.
Conflict of interest Vanessa Hartwig, Steven Dooley, Lysann Tietze and Bruno Christ participate in corporate-sponsored research collaborations with RHEACELL GmbH and Co. KG (Heidelberg, Germany). Christoph Ganss is CEO and Mark A. Kluth is CSO of RHEACELL and TICEBA GmbH (Heidelberg, Germany). Nils Tappenbeck is project manager at RHEACELL. Markus H. Frank is an inventor of ABCB5-related United States and international patents assigned to Boston Children’s Hospital and/or Brigham and Women’s Hospital (Boston, Massachusetts) and licensed to TICEBA and RHEACELL and serves as a scientific advisor to TICEBA and RHEACELL. The remaining authors have no conflicting interests. Data and data presentation are uninfluenced by TICEBA and RHEACELL.
Then in the abstract of the manuscript, “resulted from ABCB5+ cell transformation” should be “resulted from ABCB5+ cell transplantation”.
Additionally, amongst the list of authors, “Markus Frank” should be “Markus Hermann Frank”.